Felice Amato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2680133/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung, 2020, 198, 867-877.	1.4	304
2	Gut Microbiota Features in Young Children With Autism Spectrum Disorders. Frontiers in Microbiology, 2018, 9, 3146.	1.5	154
3	Gene Mutation in MicroRNA Target Sites of CFTR Gene: A Novel Pathogenetic Mechanism in Cystic Fibrosis?. PLoS ONE, 2013, 8, e60448.	1.1	72
4	Congenital Diarrheal Disorders: An Updated Diagnostic Approach. International Journal of Molecular Sciences, 2012, 13, 4168-4185.	1.8	58
5	Extensive Molecular Analysis of Patients Bearing CFTR-Related Disorders. Journal of Molecular Diagnostics, 2012, 14, 81-89.	1.2	52
6	Genotype–phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. Journal of Medical Genetics, 2017, 54, 224-235.	1.5	52
7	TrkB gene expression and DNA methylation state in Wernicke area does not associate with suicidal behavior. Journal of Affective Disorders, 2011, 135, 400-404.	2.0	46
8	Exploitation of a Very Small Peptide Nucleic Acid as a New Inhibitor of miR-509-3p Involved in the Regulation of Cystic Fibrosis Disease-Gene Expression. BioMed Research International, 2014, 2014, 1-10.	0.9	45
9	The Kelch protein NS1-BP interacts with alpha-enolase/MBP-1 and is involved in c-Myc gene transcriptional control. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1774-1785.	1.9	39
10	Two CFTR mutations within codon 970 differently impact on the chloride channel functionality. Human Mutation, 2019, 40, 742-748.	1.1	33
11	Genotype-dependency of butyrate efficacy in children with congenital chloride diarrhea. Orphanet Journal of Rare Diseases, 2013, 8, 194.	1.2	29
12	Peptide Nucleic Acids as miRNA Target Protectors for the Treatment of Cystic Fibrosis. Molecules, 2017, 22, 1144.	1.7	29
13	High-throughput screening identifies FAU protein as a regulator of mutant cystic fibrosis transmembrane conductance regulator channel. Journal of Biological Chemistry, 2018, 293, 1203-1217.	1.6	29
14	Search for SARS-CoV-2 RNA in platelets from COVID-19 patients. Platelets, 2021, 32, 284-287.	1.1	28
15	Enhanced frequency of <i>CFTR</i> gene variants in couples who are candidates for assisted reproductive technology treatment. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1289-1293.	1.4	27
16	Molecular and Functional Analysis of the Large 5′ Promoter Region of CFTR Gene Revealed Pathogenic Mutations in CF and CFTR-Related Disorders. Journal of Molecular Diagnostics, 2013, 15, 331-340.	1.2	27
17	TAS2R38 is a novel modifier gene in patients with cystic fibrosis. Scientific Reports, 2020, 10, 5806.	1.6	25
18	SARS-CoV-2 Subgenomic N (sgN) Transcripts in Oro-Nasopharyngeal Swabs Correlate with the Highest Viral Load, as Evaluated by Five Different Molecular Methods. Diagnostics, 2021, 11, 288.	1.3	25

Felice Amato

#	Article	IF	CITATIONS
19	Genetic Diseases That Predispose to Early Liver Cirrhosis. International Journal of Hepatology, 2014, 2014, 1-11.	0.4	21
20	Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Molecular Genetics & Genomic Medicine, 2021, 9, e1656.	0.6	21
21	Natural phenylalanine hydroxylase variants that confer a mild phenotype affect the enzyme's conformational stability and oligomerization equilibrium. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1435-1445.	1.8	20
22	Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis. International Journal of Molecular Sciences, 2021, 22, 8562.	1.8	20
23	A novel de novo missense mutation in <i>TP63</i> underlying germline mosaicism in AEC syndrome: Implications for recurrence risk and prenatal diagnosis. American Journal of Medical Genetics, Part A, 2012, 158A, 1957-1961.	0.7	19
24	A Novel DHPLC-Based Procedure for the Analysis of COL1A1 and COL1A2 Mutations in Osteogenesis Imperfecta. Journal of Molecular Diagnostics, 2011, 13, 648-656.	1.2	17
25	Cystic Fibrosis: The Sense of Smell. American Journal of Rhinology and Allergy, 2020, 34, 35-42.	1.0	17
26	Design, synthesis and biochemical investigation, by in vitro luciferase reporter system, of peptide nucleic acids as new inhibitors of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. MedChemComm, 2014, 5, 68-71.	3.5	16
27	Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Genes, 2021, 12, 1178.	1.0	15
28	Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics, 2021, 10, 828.	1.5	14
29	Assisting PNA transport through cystic fibrosis human airway epithelia with biodegradable hybrid lipid-polymer nanoparticles. Scientific Reports, 2021, 11, 6393.	1.6	13
30	An Update on Laboratory Diagnosis of Liver Inherited Diseases. BioMed Research International, 2013, 2013, 1-7.	0.9	10
31	A novel polymorphism in the PAI-1 gene promoter enhances gene expression. A novel pro-thrombotic risk factor?. Thrombosis Research, 2014, 134, 1229-1233.	0.8	10
32	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. Biomedicines, 2021, 9, 611.	1.4	10
33	The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD -deficient males and for the unaware carriers of pathogenic alterations of the G6PD gene. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1162-1164.	1.4	10
34	Twelve Novel Mutations in the <i>SLC26A3</i> Gene in 17 Sporadic Cases of Congenital Chloride Diarrhea. Journal of Pediatric Gastroenterology and Nutrition, 2017, 65, 26-30.	0.9	9
35	Molecular Analysis of Prothrombotic Gene Variants in Venous Thrombosis: A Potential Role for Sex and Thrombotic Localization. Journal of Clinical Medicine, 2020, 9, 1008.	1.0	8
0.1	Lung Missohiama in Custia Fibrasia Lifa 2021 11 04		

Lung Microbiome in Cystic Fibrosis. Life, 2021, 11, 94.

1.1 8

Felice Amato

#	Article	lF	CITATIONS
37	Serum galectin-3 and aldosterone: potential biomarkers of cardiac complications in patients with COVID-19. Minerva Endocrinology, 2022, 47, .	0.6	8
38	Molecular Analysis of Prothrombotic Gene Variants in Patients with Acute Ischemic Stroke and with Transient Ischemic Attack. Medicina (Lithuania), 2021, 57, 723.	0.8	7
39	Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study. PLoS ONE, 2021, 16, e0245302.	1.1	6
40	3D Chitosan-Gallic Acid Complexes: Assessment of the Chemical and Biological Properties. Gels, 2022, 8, 124.	2.1	6
41	Haemophilia A: the consequences of de novo mutations. Two case reports. Blood Transfusion, 2018, 16, 392-393.	0.3	5
42	Two cases of microvillous inclusion disease caused by novel mutations in MYO5B gene. Clinical Case Reports (discontinued), 2018, 6, 2451-2456.	0.2	4
43	Tropomyosin-related kinase B receptor polymorphisms and isoforms expression in suicide victims. Psychiatry Research, 2014, 220, 725-726.	1.7	3
44	MTHFR C677T allelic variant is not associated with plasma and cerebrospinal fluid homocysteine in amyotrophic lateral sclerosis. Clinical Chemistry and Laboratory Medicine, 2015, 53, e73-5.	1.4	2
45	Prothrombotic gene variants in acute myocardial infarction at a young age (yAMI). Rationale for tailored prevention strategies in specific risk-group subjects for acute coronary disease?. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1397-1400.	1.1	1
46	Is there an Indication for Testing the Methylenetetrahydrofolate reductase A1298C Variant in Routine Clinical Settings?. Annals of Clinical and Laboratory Science, 2021, 51, 277-279.	0.2	1
47	Editorial Comment to p.Leu636Pro mutation is associated with cystic fibrosis transmembrane conductance regulatorâ€related disorders (congenital bilateral absence of vas deferens). International Journal of Urology, 2015, 22, 804-804.	0.5	0